Literature DB >> 16043099

No evidence for tumorigenesis of AAV vectors in a large-scale study in mice.

Peter Bell1, Lili Wang, Corinna Lebherz, Douglas B Flieder, Mark S Bove, Di Wu, Guang Ping Gao, James M Wilson, Nelson A Wivel.   

Abstract

Six hundred ninety-five mice received adeno-associated virus (AAV) vectors, mostly via portal vein injection. At necropsy, the livers were inspected for tumors, and tissue sections were prepared for histology. We observed only one tumor, a lipoma, resulting in a tumor frequency of 0.14%. This tumor contained fewer vector genomes per total DNA than the surrounding liver tissue, as shown by quantitative PCR. In another mouse we found a macroscopically visible nodule containing lymphocytes. Immunohistochemistry revealed cells not of monoclonal origin, and they contained fewer AAV genomes than the surrounding hepatocytes. There were no macroscopic tumors in 226 control mice. Upon microscopic examination, lymphocytic infiltrates were found in 5% of livers of both control and vector-treated mice; no transgene expression was seen in those infiltrates in AAV-injected animals. Compared to an average frequency of spontaneous liver tumors in C57BL/6 mice (0-10%), and given the absence of high levels of vector DNA in the observed tumor, we conclude that AAV vectors do not predispose these target animals to the formation of liver tumors.

Entities:  

Mesh:

Year:  2005        PMID: 16043099     DOI: 10.1016/j.ymthe.2005.03.020

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  45 in total

1.  Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver.

Authors:  Ali Nowrouzi; Magalie Penaud-Budloo; Christine Kaeppel; Uwe Appelt; Caroline Le Guiner; Philippe Moullier; Christof von Kalle; Richard O Snyder; Manfred Schmidt
Journal:  Mol Ther       Date:  2012-03-27       Impact factor: 11.454

2.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

3.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

Review 4.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 5.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 6.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

Review 7.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

8.  rAAV-mediated tumorigenesis: still unresolved after an AAV assault.

Authors:  Paul N Valdmanis; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2012-11       Impact factor: 11.454

Review 9.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

10.  Induction of hepatocellular carcinoma by in vivo gene targeting.

Authors:  Pei-Rong Wang; Mei Xu; Sara Toffanin; Yi Li; Josep M Llovet; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.